Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesRakovina Therapeutics Inc

Rakovina Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.175 CAD 0.02 ( 12.90%)
Last update at 2026-11-03T19:31:00Z
VOLUME
65
Market Cap
2.33M

Momentum Score

…

Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company's preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. It has a research collaboration with Variational AI Inc. to identify and develop novel small-molecule therapies against DNA-damage response (DDR) targets for the treatment of cancer. Additionally, it signed a letter of intent with NanoPalm Ltd. to form a joint venture to co-develop novel small-molecule oncology therapeutics. The company was formerly known as Vincero Capital Corp. Rakovina Therapeutics Inc. is headquartered in Vancouver, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.17
Low
0.18
High
52 Week Price Range
0.09
Low
0.84
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Rakovina Therapeutics Inc (RKV.V) is a publicly listed company with limited available public information, so its specific operations and pipeline cannot be definitively described from disclosed sources. Long-term growth would depend on advancing any therapeutic candidates through research and regulatory milestones, securing partnerships or commercialization, and obtaining adequate financing; investors may find potential upside if the company substantiates clinical progress or commercial pathways.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.15
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-333.54%
Net Debt
0.11M
ROCE
-88.12%
Diluted EPS TTM
-0.62

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -4.07M -2.61M -2.79M -5.52M -
Net income -4.07M -2.61M -2.79M -5.52M -
Selling general administrative 1.45M 0.81M 0.87M 0.97M -
Reconciled depreciation 0.54M 0.54M 0.54M 0.41M -
Ebit - - - -2.47M -0.00M
Ebitda - - -2.28M -2.06M -
Operating income -3.79M -2.48M -2.82M -2.47M -
Interest expense 0.27M 0.15M - 0.00M 0.00M
Interest income 0.01M 0.02M 0.03M 0.01M -
Net interest income -0.26M -0.13M 0.03M 0.01M -
Total revenue 0.00M 0.00M 0.00M 0.00M -
Total operating expenses 3.79M 2.48M 2.82M 2.47M -
Total other income expense net -0.02M -0.00M -0.00M -3.06M -
Net income from continuing ops -4.07M -2.61M -2.79M -5.52M -
Net income applicable to common shares - - - -5.52M -0.00M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 6.24M 5.15M 6.12M 8.66M -
Intangible assets 3.98M 4.52M 5.05M 5.59M -
Total liab 1.94M 1.49M 0.11M 0.11M -
Total stockholder equity 4.30M 3.66M 6.01M 8.54M -
Other current liab - - - 0.07M 0.00M
Common stock - - - 13.57M 0.00M
Capital stock 16.45M 13.60M 13.58M 13.57M -
Retained earnings -15.00M -10.93M -8.31M -5.52M -0.00M
Cash 1.31M 0.44M 0.90M 2.81M -
Total current liabilities 1.94M 0.15M 0.11M 0.11M 0.00M
Net debt 0.11M 0.90M - - -
Short long term debt 1.42M - - - -
Total current assets 2.26M 0.63M 1.07M 3.07M 0.00M
Net tangible assets - - - 2.96M -0.00M
Net receivables 0.08M 0.02M 0.01M 0.07M 0.00M
Long term debt - 1.33M - - -
Accounts payable 0.42M 0.08M 0.03M 0.04M -
Non current assets total 3.98M 4.52M 5.05M 5.59M -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments - - 0.00M 0.80M -
Change to liabilities - - - 0.04M 0.00M
Total cashflows from investing activities - - - 0.80M 0.80M
Net borrowings 0.00M 1.51M - - -
Total cash from financing activities 4.73M 1.40M 0.00M 4.32M 0.00M
Change to operating activities - - - -0.11M -0.11M
Net income -4.07M -1.79M -2.79M -5.52M -0.00M
Change in cash 0.88M -0.46M -1.91M 2.81M 0.00M
Begin period cash flow 0.44M 0.90M 2.81M 0.00M 0.00M
End period cash flow 1.31M 0.44M 0.90M 2.81M 0.00M
Total cash from operating activities -3.86M -1.86M -1.92M -2.31M -0.00M
Issuance of capital stock 4.92M 0.00M 0.00M 4.29M -
Depreciation 0.54M 0.54M 0.54M 0.41M 0.41M
Change to account receivables - -0.01M 0.06M -0.07M -0.07M
Other cashflows from financing activities - - - - 0.00M
Change to netincome - - - 2.95M 2.95M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital -0.55M 0.02M 0.08M -0.15M -
Stock based compensation 0.08M 0.13M 0.26M 0.37M -
Other non cash items 0.13M 0.06M - 2.58M -
Free cash flow -3.86M -1.86M -1.92M -2.31M -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
RKV
Rakovina Therapeutics Inc		 0.02
12.90%		 0.17 - - - 1.12 -3.39
SHRX
Sharp Therapeutics Corp.		 -
-%		 1.37 - - - 32.37 -
NRX
NurExone Biologic Inc.		 -0.01
2.00%		 0.49 - 6.90 - 15.26 -7.24
MIR
MedMira Inc		 -
-%		 0.06 - - 223.37 - -80.03
TTI
Thiogenesis Therapeutics Corp.		 -
-%		 0.63 - - - 15.17 -58.16

Profile*

Rakovina Therapeutics Inc

Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company's preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. It has a research collaboration with Variational AI Inc. to identify and develop novel small-molecule therapies against DNA-damage response (DDR) targets for the treatment of cancer. Additionally, it signed a letter of intent with NanoPalm Ltd. to form a joint venture to co-develop novel small-molecule oncology therapeutics. The company was formerly known as Vincero Capital Corp. Rakovina Therapeutics Inc. is headquartered in Vancouver, Canada.

999 West Broadway, Vancouver, BC, Canada, V5Z 1K5

https://www.rakovinatherapeutics.com

Name Title Year Born
Mr. Jeffrey A. Bacha B.Sc., M.B.A. Exec. Chairman 1968
Dr. Mads Daugaard Pres & Chief Scientific Officer NA
Mr. David Hyman CA, CBV CFO & Corp. Sec. 1973
Dr. John Langlands Ph.D. Chief Operating Officer NA
Mr. Jeffrey A. Bacha B.Sc., M.B.A. Executive Chairman 1968
Dr. Mads Daugaard Ph.D. President, CEO & Chief Scientific Officer NA
Mr. David Hyman CA, CBV CFO & Corporate Secretary 1973
Dr. David M. Kideckel M.B.A., MBA, Ph.D. CFO & Director 1981
Ms. Michelle Seltenrich M.B.A., MBA Director of Corporate Development NA
Dr. David M. Kideckel M.B.A., Ph.D. CFO & Director 1980

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…